KOD

Kodiak is a clinical-stage biologics company that, in its own words, has "not generated any product revenue" and does not expect to "unless and until we obtain regulatory approval." The five-year history is an unbroken string of losses (-$267M, -$334M, -$260M, -$176M, -$230M) funding an accumulated deficit that has reached -$1.56B. FY2025 net loss widened back to -$230M (YoY -30.5%) as R&D spend jumped +44.6% to $182M — the company is spending more to push its candidates forward, which is the entire point of owning it, but there is no commercial engine underneath. Return on equity is -146% and operating cash flow is -$136M; there is nothing here to value on fundamentals or conventional multiples (no revenue means no P/S, persistent losses mean no P/E).

The balance sheet is the crux. Cash of $209.9M against a ~$136M annual operating burn is management's stated basis for funding operations only "into 2027," and the MD&A states plainly there is "substantial doubt regarding our ability to continue as a going concern." The runway was bought with dilution: in December 2025 Kodiak sold 8M shares at $23.00 for $173M net, lifting shares outstanding +17.3% to 61.8M — and the filing warns more is coming ("our stockholders will experience dilution"). Current liabilities also spiked +78.1%. So even before any clinical readout, the holder faces a near-certain future capital raise at an unknown price, with the equity offering struck at $23 versus today's $37.74 underscoring how much the stock can swing on financing terms alone.